Nawel is a biochemist, having undertaken her PhD with Dr. A. De Agostini (Department of Pathology and Immunology) at the Faculty of Medicine, University of Geneva. She investigated the role of aHSPG post biosynthetic modification and its implication on endometrial cancer invasion and angiogenesis (2015-2020). She is currently doing her postdoc working on targeting BRCA mutated ovarian cancer resistant to PARP inhibitors. Nawel has been important for the development of organoid cell lines.